A
Anna Tsimelzon
Researcher at Baylor College of Medicine
Publications - 80
Citations - 6636
Anna Tsimelzon is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 36, co-authored 79 publications receiving 5923 citations. Previous affiliations of Anna Tsimelzon include University of California, Santa Cruz & Houston Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein,Anna Tsimelzon,Graham M. Poage,Kyle R. Covington,Alejandro Contreras,Suzanne A. W. Fuqua,Michelle I. Savage,C. Kent Osborne,Susan G. Hilsenbeck,Jenny C. Chang,Gordon B. Mills,Ching C. Lau,Powel H. Brown +12 more
TL;DR: There are four stable TNBC subtypes characterized by the expression of distinct molecular profiles that have distinct prognoses, and novel subtype-specific targets that can be targeted in the future for the effective treatment of TNBCs are identified.
Journal ArticleDOI
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
Jenny C. Chang,Eric C. Wooten,Anna Tsimelzon,Susan G. Hilsenbeck,M. Carolina Gutierrez,Richard M. Elledge,Syed K. Mohsin,C. Kent Osborne,Gary C. Chamness,D. Craig Allred,Peter O'Connell +10 more
TL;DR: It is postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel, and these molecular profiles could allow development of a clinical test for docetAXel sensitivity, thus reducing unnecessary treatment for women with breast cancer.
Journal ArticleDOI
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
Suleiman Massarweh,C. Kent Osborne,Chad J. Creighton,Lanfang Qin,Anna Tsimelzon,Shixia Huang,Heidi L. Weiss,Mothaffar F. Rimawi,Rachel Schiff +8 more
TL;DR: EGFR/HER2 may mediate tamoxifen resistance in ER-positive breast cancer despite continued suppression of ER genomic function by tamox ifen, providing a rationale to combine HER inhibitors with tamoxIFen in clinical studies, even in tumors that do not initially overexpress EGFR/ HER2.
Journal ArticleDOI
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
Xiaomei Zhang,Sofie Claerhout,Aleix Prat,Lacey E. Dobrolecki,Ivana Petrovic,Qing Lai,Melissa D. Landis,Lisa Wiechmann,Rachel Schiff,Mario Giuliano,Helen Wong,Suzanne W. A. Fuqua,Alejandro Contreras,Carolina Gutierrez,Jian Huang,Jian Huang,Sufeng Mao,Anne Pavlick,A. Froehlich,Meng Fen Wu,Anna Tsimelzon,Susan G. Hilsenbeck,Edward S. Chen,Pavel Zuloaga,Chad A. Shaw,Mothaffar F. Rimawi,Charles M. Perou,Gordon B. Mills,Jenny C. Chang,Michael T. Lewis +29 more
TL;DR: Serially passaged xenografts show biologic consistency with the tumor of origin, are phenotypically stable across multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses as those observed clinically.
Journal ArticleDOI
Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
Zachary C. Hartman,Graham M. Poage,Petra den Hollander,Anna Tsimelzon,Jamal Hill,Nattapon Panupinthu,Yun Zhang,Abhijit Mazumdar,Susan G. Hilsenbeck,Gordon B. Mills,Powel H. Brown +10 more
TL;DR: A Cox multivariable analysis of patient specimens revealed that IL-6 and IL-8 expression predicted patient survival times, offering a rationale for dual inhibition of IL- 6/IL-8 signaling as a therapeutic strategy to improve outcomes for patients with TNBCs.